&lt;p&gt;Tumor Response to Irinotecan is Associated with IL-10 Expression Level in Metastatic Colorectal Cancer-Results from mCRC Biomarker Study&lt;/p&gt;

Chang, Jinjia; Zhang, Wen; Lin, Guang-Yi; Tong, Duo; Zhu, Dan; Zhao, Jingbo; Yu, Qihe; Huang, Dan; Li, Wenhua

doi:10.2147/ott.s275636

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-10 promotes immune suppression in TME [ 26 , 27 ], but surprisingly, the reduction predicts poor outcomes in lung and colon cancer [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib

Abbona

Ricci²,

Paccagnella

et al. 2023

Vaccines

View full text Add to dashboard Cite

Metastatic colorectal cancer is frequently associated with poor clinical conditions that may limit therapeutic options. Regorafenib is a small molecule approved for the treatment of metastatic colorectal cancer, but it is hampered by significative toxicities. Moreover, only a relatively limited number of patients benefit from the treatment. Therefore, the identification of reliable markers for response is an unmet need. Eighteen cytokines, selected based on their prevalent Th1 or Th2 effects, were collected. Peripheral blood samples were gathered at baseline in 25 metastatic colorectal cancer patients treated with regorafenib. Data extracted have been linked to progression-free survival. ROC identified the best cytokines associated with outcome. The relative value of the selected cytokines was determined by PCA. Data analysis identified 8 cytokines (TGF-β, TNF-α, CCL-2, IL-6, IL-8, IL-10, IL-13 and IL-21), used to create a signature (TGF-β, TNF-α high; CCL-2, IL-6, IL-8, IL-10, IL-13 and IL-21 low) corresponding to patients with a significantly longer progression-free survival. This report suggests that the analysis of multiple cytokines might identify a cytokine signature related to a patient’s outcome that is able to recognize patients who will benefit from treatment. If confirmed, future studies, also based on different drugs, using this approach and including larger patient populations, might identify a signature allowing the a priori identification of patients to be treated.

show abstract

“…IL-10 promotes immune suppression in TME [ 26 , 27 ], but surprisingly, the reduction predicts poor outcomes in lung and colon cancer [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%